Aethlon's 'Pipeline Device' Tackles Cancer and Long COVID Amid Financial Headwinds

SAN DIEGO, CA – February 12, 2026 – Aethlon Medical, Inc. (Nasdaq: AEMD) today outlined a strategy of aggressive scientific advancement paired with stringent financial discipline, as it progresses with its flagship Hemopurifier® technology. In its fiscal third-quarter update, the clinical-stage company highlighted ongoing progress in an Australian oncology trial, promising preclinical data for Long COVID, and efforts to simplify its treatment delivery, all while navigating the financial pressures common in the biotech sector.

The company is championing its Hemopurifier as a potential "pipeline within a single device," an investigational tool designed to filter harmful, virus-sized particles from the blood. This core technology is now being tested across a widening spectrum of debilitating diseases, from advanced cancer to the persistent symptoms of Long COVID.

A 'Pipeline in a Single Device'

The central premise of Aethlon’s technology is the removal of extracellular vesicles (EVs) from circulation. These microscopic particles, shed by cells, act as messengers that can carry problematic cargo. In cancer, tumor-derived EVs are believed to help tumors evade the immune system and metastasize. In viral illnesses, they can transport viral components and inflammatory signals throughout the body.

The Hemopurifier, which has received U.S. FDA Breakthrough Device Designation for both cancer and life-threatening viruses, uses an extracorporeal blood circuit to filter these EVs. Blood is drawn from the patient, passed through the device containing a proprietary plant-based lectin resin that binds to the EVs, and then returned to the body.

This mechanism is currently under evaluation in a nine-to-18-patient oncology trial in Australia. The study is enrolling individuals with solid tumors whose disease is stable or progressing despite treatment with powerful anti-PD-1 immunotherapies like Keytruda® or Opdivo®. Following a first cohort that showed what the company called "favorable directional improvements" in EV and immune cell counts, enrollment and treatment for the second cohort are now actively underway. Two participants in this second group have already completed two Hemopurifier treatments. Data from the first three patients of this cohort is expected to be presented to an independent Data Safety Monitoring Board (DSMB) in late March, a critical milestone that will determine if the trial can proceed to the next stage involving more frequent dosing.

Beyond cancer, Aethlon is generating buzz with its preclinical research into Long COVID. In a study conducted with the UCSF Medical Center Long COVID clinic, researchers found that the Hemopurifier’s resin successfully bound and removed elevated levels of specific EVs from the plasma of Long COVID patients. The findings, published on the preprint server bioRxiv and now submitted for peer review, also showed the device removed several microRNAs associated with inflammatory pathways, including the JAK-STAT pathway, which is a target in other Long COVID clinical trials. Given that millions suffer from Long COVID with no proven effective treatments, these early findings suggest a novel therapeutic avenue.

Building on this research, Aethlon is exploring the Hemopurifier's potential in a host of other diseases where EVs are implicated, including Lupus, Rheumatoid Arthritis, Multiple Sclerosis, and Sepsis, reinforcing its vision of a single platform with multi-disease applications.

The Balancing Act of Biotech Finance

While the scientific narrative is one of expansion and potential, the financial story is one of careful management and looming capital needs. Aethlon highlighted its operational efficiency, noting that consolidated operating expenses for the nine months ended December 31, 2025, declined a significant 26.9% to $5.36 million compared to $7.34 million in the prior year.

However, the most recent quarter showed a reversal of this trend. Operating expenses for the third quarter rose 13.6% to $2.06 million, driven primarily by higher payroll costs. This contributed to an increased operating loss for the quarter and a net loss of $2.02 million.

More critically, the company reported a cash balance of approximately $7.0 million. In its forward-looking statements, Aethlon acknowledged this cash on hand "may not be sufficient to support operations for the next 12 months without additional financing." This underscores the classic challenge for clinical-stage biotechs: balancing a high R&D burn rate with the need to secure continuous funding to reach key clinical and regulatory milestones.

This financial pressure is reflected in the company's recent stock history. In October 2025, Aethlon received a non-compliance notice from Nasdaq for its stock trading below the $1.00 minimum bid price. Management acted swiftly, executing a 1-for-10 reverse stock split to regain compliance, a move that resolved the immediate issue but also reflected the stock's preceding challenges. While the company confirmed all prior compliance matters are resolved, maintaining its Nasdaq listing remains a stated risk factor dependent on future performance and market valuation.

Paving the Way for Broader Access

Looking toward future commercialization, Aethlon is proactively addressing a key logistical hurdle for blood purification therapies: complexity. The company is collaborating with Stavro to evaluate the Hemopurifier's compatibility with the SLAMB system, a simplified blood treatment platform.

Success in this endeavor could be transformative for the Hemopurifier's accessibility. A primary goal is to enable the device's use in standard oncology units and infusion centers, eliminating the current need for large dialysis catheters, bulky dialysis machines, and the on-site supervision of a nephrologist. By simplifying the treatment process, Aethlon hopes to democratize access to its therapy, making it a more feasible option for a much broader range of healthcare facilities and patients.

This forward-thinking approach, combined with its diverse research programs, paints a picture of a company with significant ambition. Aethlon is at a pivotal juncture, where promising, multi-faceted science is running headlong into the stark financial realities of the biotech industry. The outcome of the upcoming DSMB review for its oncology trial and its ability to secure further funding will be critical in determining whether the potential of its 'pipeline within a device' can be fully realized.